Aatur Singhi, MD PhD

A tweetorial on our study (gastrojournal.org/article/S0016-…). But, first a case: Young female w/ a 1.9 cm incidental pancreatic cyst. No concerning features, but KRAS, TP53 and SMAD4 mutations on molecular testing. Surgical resection: #IPMN w/ a small #PancreaticCancer. #Pathology #GIPath

Exciting research by @DelgoffeLab on how eating primes immune cells for action! More here- nature.com/articles/d4158… I was thrilled to recently have Dr. Greg Delgoffe join me on an episode of #TheImmunoVerse podcast to explore how the tumor microenvironment functions as a complex, dynamic ecosystem that shapes the success or failure of cancer #immunotherapy. 🎧 Check it out now at Moffitt.org/ImmunoVerse or on your favorite podcast platform.

Now on @ModernPathology our study describing intraductal papillary squamous neoplasm (IPSN), a new entity among intraductal precursors of pancreatic cancer. It is the first demonstration that pancreatic cancer can arise also from squamous precursors. modernpathology.org/article/S0893-…

#Thrilled, #Humbled and #Inspired to join #NCIDirector @DrTonyLetai and #NCILeadership and the Directors of all of the USA @theNCI Cancer Centers today! #ClinicalTrials #CancerPrevention #RuralCancerCare #AccessForAll #NewTherapies #CancerSurvivorship @wakeforestmed

Thanks @WRAL for highlighting our work and raising #PancreaticCancer awareness. So wonderful to celebrate @cjder23 at the Steelman Symposium. @UNC_Lineberger @UNC_PHCO

Make sure to tune in next week to @ImmunoPodcast for an exciting interview with our B cell expert, Dr. Tullia Bruno (@BcellBruno). @UPMCnews @pitt_immunology @PittHealthSci

Thrilled to see this exciting work from our founder @RongFan8 and collaborators published in Nature Communications. Using Epi-Patho-DBiT spatial multiomics technology, the team mapped chromatin accessibility and histone modifications directly from FFPE tissues to reveal genomic and epigenetic mechanisms driving lymphoma transformation. Congratulations to the entire team on this outstanding achievement and impactful contribution to spatial epigenomics research. 👏 Read the paper: nature.com/articles/s4146… #SpatialBiology #SpatialEpigenomics #FFPE #Multiomics #CancerResearch

Trial by trial, step by step How precision medicine improved outcomes in ALK-positive lung cancer (which typically affects younger, non-smokers):

🚨 Out today in Cell! @CellCellPress Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale. 📄 doi.org/10.1016/j.cell… 🧵1/8

@ZhiVenFongMD @UPMC ARX, along with ALT (ATRX/DAXX loss). Excellent manuscript by my good friend Lodewijk Brosens (pmc.ncbi.nlm.nih.gov/articles/PMC72…). In contrast, PDX1 is characteristic of indolent insulinomas. These markers may help in longterm prognostication but maybe more so for surgical planning?

@PancPathologist @UPMC Astute point, always learning from you @PancPathologist! ATRX ➡️ Whipple PDX1 ➡️ Enucleation?

Large 3 cm uncinate insulinoma abutting the pancreatic duct in a medically comorbid patient. Would you do a whipple or try to enucleate? We did the latter in the video below. Should we be more aggressive with selecting patients for enucleation? youtu.be/SK0Lcdo8qWI?si…

We're seeing major advances vs pancreatic cancer. Today @NEJM data for daraxonrasib @RevMedicines nejm.org/doi/full/10.10… Context for this first-in-class molecular glue nejm.org/doi/full/10.10…

New @Cancer_Cell paper on mechanisms of resistance to @RevMedicines Daraxonrasib Disrupted molecular glue complex drives RAS inhibitor resistance cell.com/cell/fulltext/… 18/40 genomic alterations in RAS pathway (👇🏽) Recurrent RAS Y64 alteration attenuates tri-complex formation

Amazing talk by Melissa Hogg on robotics @ddw

New @Nature study: >50% of lung cancer metastases are seeded by other metastases, not the primary tumor. This "seeding from seeding" reveals a complex evolutionary cascade that allows cancer to colonize the body. nature.com/articles/s4158…

🧠 Can we better predict which pancreatic cysts may become cancerous? 🧠 New study from authors Drs. DeWitt & Easler shows the PancreaSeq Genomic Classifier boosts accuracy for cyst classification and advanced neoplasia detection. #ManuscriptMonday ow.ly/UapS50YzeZ7

Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 💊 Expanded access is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational medicines outside of a clinical trial when they are unable to participate in a clinical trial and all other appropriate treatment options have been exhausted. In response to the FDA’s letter, Revolution Medicines said that this “represents a critical step in the process of opening an EAP” and that they are “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States,” according to a statement from the company. Read Revolution Medicines’ Expanded Access Policy, including how to submit a request through a licensed treating physician and how daraxonrasib is extending survival for #pancreaticcancer patients at 🔗 pcan.at/rjul9sza.

The @US_FDA has issued a "safe to proceed" letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer. Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians on behalf of eligible patients. #FDA #PancreaticCancer fda.gov/news-events/pr…

@UMICHpancreas @Fil_Bednar Awesome news! 👏

Last evening we celebrated the installation of Filip Bednar, MD, PhD as the Maud T. Lane Research Professor in Surgical Oncology. A distinguished pancreatic surgeon, brilliant researcher and highly respected teacher and mentor. Congratulations, Dr. Bednar! @Fil_Bednar @timofran1 @LyssiotisLab @Pasca_Lab

Must read. 👇🏼👇🏼 PancreaSeq Genomic Classifier (PancreaSeq GC) Improves Pancreatic Cyst Classification and Detection of Advanced Neoplasia: A Multi-institutional Validation Study @annsurgoncol @pancpathologist link.springer.com/article/10.124…